Cargando…
Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study
BACKGROUND: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of p...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815199/ https://www.ncbi.nlm.nih.gov/pubmed/27036739 http://dx.doi.org/10.1186/s12936-016-1240-7 |
_version_ | 1782424560659857408 |
---|---|
author | Tun, Kyaw Myo Jeeyapant, Atthanee Imwong, Mallika Thein, Min Aung, Sai Soe Moe Hlaing, Tin Maung Yuentrakul, Prayoon Promnarate, Cholrawee Dhorda, Mehul Woodrow, Charles J. Dondorp, Arjen M. Ashley, Elizabeth A. Smithuis, Frank M. White, Nicholas J. Day, Nicholas P. J. |
author_facet | Tun, Kyaw Myo Jeeyapant, Atthanee Imwong, Mallika Thein, Min Aung, Sai Soe Moe Hlaing, Tin Maung Yuentrakul, Prayoon Promnarate, Cholrawee Dhorda, Mehul Woodrow, Charles J. Dondorp, Arjen M. Ashley, Elizabeth A. Smithuis, Frank M. White, Nicholas J. Day, Nicholas P. J. |
author_sort | Tun, Kyaw Myo |
collection | PubMed |
description | BACKGROUND: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventive and curative treatment in the region, but its therapeutic efficacy has fallen in Cambodia. METHODS: A prospective clinical and parasitological evaluation of DP was conducted at two sites in Upper Myanmar between August 2013 and December 2014, enrolling 116 patients with acute uncomplicated falciparum malaria. Patients received DP orally for 3 days together with primaquine 0.25 mg/kg on admission. Parasite clearance half-lives based on 6 hourly blood smears, and day 42 therapeutic responses were assessed as well as parasite K13 genotypes. RESULTS: Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21 % of patients. Delayed parasite clearance was significantly associated with mutations in the propeller region of the parasite k13 gene. The k13 F446I mutation was found in 25.4 % of infections and was associated with a median clearance half-life of 4.7 h compared with 2.7 h for infections without k13 mutations (p < 0.001). There were no failures after 42 days of follow-up, although 18 % of patients had persistent parasitaemia on day 3. CONCLUSION: The dominant k13 mutation observed in Upper Myanmar, F446I, appears to be associated with an intermediate rate of parasite clearance compared to other common mutations described elsewhere in the Greater Mekong Subregion. Discerning this phenotype requires relatively detailed clearance measurements, highlighting the importance of methodology in assessing artemisinin resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1240-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4815199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48151992016-04-01 Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study Tun, Kyaw Myo Jeeyapant, Atthanee Imwong, Mallika Thein, Min Aung, Sai Soe Moe Hlaing, Tin Maung Yuentrakul, Prayoon Promnarate, Cholrawee Dhorda, Mehul Woodrow, Charles J. Dondorp, Arjen M. Ashley, Elizabeth A. Smithuis, Frank M. White, Nicholas J. Day, Nicholas P. J. Malar J Research BACKGROUND: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventive and curative treatment in the region, but its therapeutic efficacy has fallen in Cambodia. METHODS: A prospective clinical and parasitological evaluation of DP was conducted at two sites in Upper Myanmar between August 2013 and December 2014, enrolling 116 patients with acute uncomplicated falciparum malaria. Patients received DP orally for 3 days together with primaquine 0.25 mg/kg on admission. Parasite clearance half-lives based on 6 hourly blood smears, and day 42 therapeutic responses were assessed as well as parasite K13 genotypes. RESULTS: Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21 % of patients. Delayed parasite clearance was significantly associated with mutations in the propeller region of the parasite k13 gene. The k13 F446I mutation was found in 25.4 % of infections and was associated with a median clearance half-life of 4.7 h compared with 2.7 h for infections without k13 mutations (p < 0.001). There were no failures after 42 days of follow-up, although 18 % of patients had persistent parasitaemia on day 3. CONCLUSION: The dominant k13 mutation observed in Upper Myanmar, F446I, appears to be associated with an intermediate rate of parasite clearance compared to other common mutations described elsewhere in the Greater Mekong Subregion. Discerning this phenotype requires relatively detailed clearance measurements, highlighting the importance of methodology in assessing artemisinin resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1240-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-31 /pmc/articles/PMC4815199/ /pubmed/27036739 http://dx.doi.org/10.1186/s12936-016-1240-7 Text en © Tun et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Tun, Kyaw Myo Jeeyapant, Atthanee Imwong, Mallika Thein, Min Aung, Sai Soe Moe Hlaing, Tin Maung Yuentrakul, Prayoon Promnarate, Cholrawee Dhorda, Mehul Woodrow, Charles J. Dondorp, Arjen M. Ashley, Elizabeth A. Smithuis, Frank M. White, Nicholas J. Day, Nicholas P. J. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
title | Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
title_full | Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
title_fullStr | Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
title_full_unstemmed | Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
title_short | Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
title_sort | parasite clearance rates in upper myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815199/ https://www.ncbi.nlm.nih.gov/pubmed/27036739 http://dx.doi.org/10.1186/s12936-016-1240-7 |
work_keys_str_mv | AT tunkyawmyo parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT jeeyapantatthanee parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT imwongmallika parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT theinmin parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT aungsaisoemoe parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT hlaingtinmaung parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT yuentrakulprayoon parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT promnaratecholrawee parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT dhordamehul parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT woodrowcharlesj parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT dondorparjenm parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT ashleyelizabetha parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT smithuisfrankm parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT whitenicholasj parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy AT daynicholaspj parasiteclearanceratesinuppermyanmarindicateadistinctiveartemisininresistancephenotypeatherapeuticefficacystudy |